# A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

> **NCT03201965** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 416 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone, 40 mg
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT03201965
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-05
- **Primary completion:** 2020-02-14
- **Final completion:** 2024-11-19
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03201965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03201965, "A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03201965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*